Detalhe da pesquisa
1.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1899-1909, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951374
2.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130806
3.
Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
Antimicrob Agents Chemother
; 66(2): e0091621, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871089
4.
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
Clin Infect Dis
; 70(7): 1344-1352, 2020 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31121015
5.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
AIDS Behav
; 24(12): 3533-3544, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32447500
6.
Preexposure prophylaxis for HIV infection among African women.
N Engl J Med
; 367(5): 411-22, 2012 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22784040
7.
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
AIDS Behav
; 19(5): 743-51, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25100053
8.
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Lancet HIV
; 9(5): e309-e322, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489376
9.
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
Antivir Ther
; 26(6-8): 95-105, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35485339
10.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Lancet HIV
; 7(1): e16-e26, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31740348
11.
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
PLoS One
; 13(10): e0205368, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30352054
12.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Lancet HIV
; 5(5): e211-e220, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29592840
13.
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Lancet HIV
; 4(1): e13-e20, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27815068
14.
Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics.
Pediatr Infect Dis J
; 35(11): 1215-1221, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27294305
15.
Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
J Acquir Immune Defic Syndr
; 67(5): 555-63, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25393942
16.
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
J Acquir Immune Defic Syndr
; 66(3): 324-31, 2014 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25157647
17.
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
BMC Pharmacol Toxicol
; 15: 77, 2014 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25539648